A Study Evaluating MM-310 in Patients With Solid Tumors

Purpose:	For patients with solid tumors (not just uterine sarcoma): To study whether targeting a specific tumor protein on cancer cells, called the EphA2 receptor can allow a well know chemotherapy: docetaxel to be delivered directly to where the tumor is rather than affecting all tissues (including healthy tissue) similarly. The drug is called MM-310 and consists of a liposome (a microscopic lipid + drug combination wrapped within a membrane).
Authoritative site for this trial:	At ClinicalTrials.gov
What is the treatment?	MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.
Is there a chance you'll get a placebo?	No. It’s an open label trial with no placebo arm (see glossary)
How old do you have to be?	At least 18
What phase study is this?	Phase I (see glossary)
What includes you in trial?	The cancer itself should be reachable for biopsy and you should be willing to have the biopsy. You are able to move around and do basic self-care. Liver, kidneys and blood tests close to normal. Not pregnant and avoiding pregnancy (abstain/prophylaxis) Recovered from prior cancer therapy.
What excludes you from the trial?	Treatment with docetaxel within 6 months before starting this new treatment. Metastases to brain or spinal cord. Prior treatment with MM-310 received any other cancer treatment in the prior 14 days. Treatment with anti-VEGF/VEGFR drugs that has not yet had a chance to “wash” away. Severe neuropathy (nerve pain/nerve damage).
In USA?	Yes
Sites where the trial is offered:	Honor Health, Scottsdale, Arizona, United States, 85259 University California San Francisco, San Francisco, California, United States, 94143 MinnesotaMayo ClinicRecruitingRochester, Minnesota, United States, 55902 New YorkRoswell Park Cancer Institute, Buffalo, New York, United States, 14263 Duke University, Durham, North Carolina, 27710
Contact information:	Vasileios Askoxylakis, MD, PhD Tel. 617.441.7492 VAskoxylakis@merrimack.com